Effects of anti-TNF therapy and immunomodulators on anxiety and depressive symptoms in patients with inflammatory bowel disease: a 5-year analysis.

Details

Ressource 1Download: 34484421_BIB_C12591E2DD8F.pdf (1680.23 [Ko])
State: Public
Version: Final published version
License: CC BY-NC 4.0
Serval ID
serval:BIB_C12591E2DD8F
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Effects of anti-TNF therapy and immunomodulators on anxiety and depressive symptoms in patients with inflammatory bowel disease: a 5-year analysis.
Journal
Therapeutic advances in gastroenterology
Author(s)
Siebenhüner A.R., Rossel J.B., Schreiner P., Butter M., Greuter T., Krupka N., Jordi SBU, Biedermann L., Rogler G., Misselwitz B., von Känel R.
ISSN
1756-283X (Print)
ISSN-L
1756-283X
Publication state
Published
Issued date
2021
Peer-reviewed
Oui
Volume
14
Pages
17562848211033763
Language
english
Notes
Publication types: Journal Article
Publication Status: epublish
Abstract
Anxiety and depression are prevalent in patients with inflammatory bowel diseases (IBD), especially during IBD flares. IBD therapies can profoundly affect the mood of patients with IBD. We aimed to determine the long-term impact of anti-tumor necrosis factor (anti-TNF) and immunomodulators (IM) on anxiety and depressive symptoms in IBD patients.
We compared three treatment groups with IM only (group A), anti-TNF ± IM (group B) and no such therapy (group C). Patients completed the hospital anxiety and depression scale (HADS) at 1 year, 3 years, and 5 years after start of treatment.
In total, 581 patients with IBD (42.9% Crohn's disease, 57.1% ulcerative colitis/IBD unclassified) participated in this study. Effects of treatment were analyzed in a mixed effects model, with and without correction for confounders. Compared with group C, group B showed a significant treatment-related improvement in both anxiety and depressive symptoms within the first 2.5 years and also thereafter. Group A showed a significant long-term improvement of anxiety and both short-term and long-term improvement in depressive symptoms. The significance of these results was maintained after correction for confounders, including corticosteroid treatment. Additionally, both groups A and B showed a significant decrease in disease activity in the first 2.5 years after start of treatment and also thereafter. Anti-TNF and IM treatment were associated with a similarly significant decrease in anxiety and depressive symptoms over an observation period of up to 5 years.
Besides a clear benefit for disease activity, anti-TNF and IM apparently improve the mood of patients with IBD.
Keywords
anti-TNF, anxiety, depressive symptoms, hospital anxiety and depression scale, immune-modulatory therapy, inflammatory bowel disease, mood, psychosocial factors
Pubmed
Web of science
Open Access
Yes
Create date
04/10/2021 12:32
Last modification date
09/08/2024 15:05
Usage data